Tevogen AI

Tevogen.AI at @FABConSQLCon Tevogen CIO and @Head_TevogenAI, Mittul Mehta, speaking to building an AI-ready data foundation to power precision immunotherapy, transforming complex scientific data spanning millions of protein sequences and hundreds of millions of peptides. $TVGN $MSFT #AI #Biotech #FabCon #Microsoft #PrecisionMedicine #BigData #Analytics

Honored to see Tevogen.AI recognized by @Microsoft at #FabCon as an ISV. AI in biotech is shifting from models to systems—continuous learning, real-world feedback, and scale. Just getting started. #AI #Biotech $TVGN $MSFT @arunulag

📰 globenewswire.com/news-release/2… @Head_TevogenAI Mittul Mehta, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value.” @TevogenAI $TVGN #PredicTcell #artificialintelligence #DrugDiscovery #immunotherapy

"What are you actually seeing from PredicTcell?" Early beta: Recall up to 92%, Precision to 48%, true positives rising. Built on 665M+ peptides, solving a real gap in precision immunotherapy. Preliminary results, but I'm comfortable sharing them. $TVGN #Biotech #AI

📰 globenewswire.com/news-release/2… Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus $TVGN #Sciometrix #Clinicus #HealthcareTechnology #Revenue #Strategy @TevogenBio @TevogenAI

📢 From Mittul Mehta, Tevogen CIO and @Head_TevogenAI. Most companies celebrate going public. We used it as a starting gun. Two years ago, Tevogen went public at Nasdaq - A day I’ll always remember for the energy, the optimism, and the responsibility that comes with running a public company. Then the morning after, the real work began. When we stood up Tevogen.AI, the conviction was clear: AI wasn't going to be a support function. It was going to be a frontier capability that fundamentally changed how we read, understand, and act on complex biological data. Simple in conviction. Hard in execution. Since then, the teams have gone from thesis to tangible: 655 million unique peptides, models scaling nearly 20x between training cycles, and a platform built to compound as the science advances. None of that came from moving fast for its own sake. It came from disciplined decisions — what to build, what to buy, and where partnerships produced durable leverage. What excites me most isn't what's already been achieved… It's what's next. As we close out beta training for PredicTcell™ and move into AdapTcell™, the platform is transitioning from experimentation to operational reality. The feedback loop between our AI and biology teams is tightening with every cycle and increasing learning velocity. Two years on, the work feels less about celebration and more about momentum, which is exactly where it should be. For leaders building AI at scale: where are you seeing the biggest gap between experimentation and execution? #AIinBiotech #LifeSciences #TechnologyStrategy #Leadership $TVGN #Board #CIO #AIPlatforms #PublicCompany #BoardPerspective #TechnologyLeadership

📰 globenewswire.com/news-release/2… “Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.” - @DrRyanSaadi $TVGN #CorporateGovernance #EquityIncentives #RevenueFocus #GrowthStrategy #HealthcareAI

📢 From Mittul Mehta, Tevogen CIO and Head of @TevogenAI Reflecting on the past year at Tevogen.AI, I’m proud to share a snapshot of what we’ve built, and where we’re headed. Through strategic partnerships with @Databricks and @Microsoft, our team has developed a highly curated dataset spanning ~24 million proteins. Using our proprietary data refinement processes, this has expanded into a library of 655 million unique peptides, with nearly 16 billion data points across 12 clinical conditions and the known human genome. By cross-referencing this work with 37 million expert scientific articles, we’ve been able to enrich our datasets, uncover critical biochemical properties of amino acid chains, identify key anchor residues, and sharpen HLA specificity at scale. On the modeling front, our PredicTcell™ journey has accelerated rapidly. While the alpha model was trained on ~100,000 data points and served as an important benchmark, the beta version now incorporates 1.8 million data points, representing nearly a 20-fold scale-up. As we wrap the PredicTcell™ beta and begin training AdapTcell™, I’m excited to continue sharing progress as Tevogen.AI advances toward what many consider the Holy Grail of immunology: Predicting the proteome for any given protein–HLA combination. More to come. @drhew @hoifungpoon @TevogenAI @Microsoft @databricks $TVGN #TevogenAI #AIinBiotech #ComputationalBiology #Immunology #PrecisionMedicine #MachineLearning

🎙Q&A with Tevogen CEO🎙 Q. As Tevogen continues to build long-term value, how do you think about capital allocation and sharing that success with shareholders over time? A. I’ve always believed that when a company succeeds, shareholders should share in that success. I am supportive of the Board evaluating a potential one-time special cash dividend in the context of future performance, which is obviously subject to Board approval. I personally believe returning capital to shareholders is critical for long term value creation for any high growth enterprise. - @DrRyanSaadi $TVGN #affordable #accessible #celltherapy #JPM2026 @Tevogen @TevogenAI

📰 globenewswire.com/news-release/2… 🔹Platform & Manufacturing Progress: Advanced the ExacTcell™ platform in 2025, improving CTL yield, consistency, and throughput while progressing toward in-house GMP manufacturing capabilities. 🔹Pipeline Expansion: Expanded the CTL pipeline across multiple viral and oncology indications, including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers, supported by @TevogenAI. 🔹Execution & Value Creation: Achieved key scientific and operational milestones positioning Tevogen as a scalable, multi-program cell therapy organization with a foundation for long-term value creation. $TVGN #affordable #accessible #celltherapy #JPM2026

Meet Tevogen leadership at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 12-15, 2026. All meeting requests are coordinated via ir@tevogen.com $TVGN @TevogenBio @TevogenAI #JPM26 #JPM2026 #affordable #accessible #celltherapy

“Dr. Patton’s leadership and scientific vision have played a pivotal role in shaping Tevogen’s foundation,” said @DrRyanSaadi, Founder & CEO of @Tevogen. “His legacy at Yale reinforces the strength of the Company’s mission during a period of significant momentum.” 📰 globenewswire.com/news-release/2… @Tevogen @TevogenAI @Yale @YaleSPH @YaleMed

🍂 As we approach Thanksgiving, we cannot think of a better time to express our immense gratitude to each of you for embracing our mission. Wishing you and those you hold dearest a Happy Thanksgiving, filled with health, love, and gratitude.🍃 $TVGN

American patients have waited long enough. America needed a healthcare enterprise that didn’t require billions. They said it was impossible. They were wrong. 5.5 years. ~$40M. Founders still own the majority and the mission. Meet Tevogen 🇺🇸 — a purpose-driven healthcare enterprise built by a team with >300 years of combined experience across healthcare, economics, AI, and yes - investment banking and finance. It started with so-called “biotech” product development, whatever that word even means anymore beyond marketing and outdated financial literacy. Simple translation for anyone still using 1970s vocabulary: 🔹Pharma = chemistry
(such as Na + Cl → NaCl: normal saline. In other words, salt.) 🔹#Biotech = engineering living systems, such as cell therapies and antibodies, which, ironically, now make up the majority of most “#pharma” pipelines and portfolios. @TevogenAI : A pioneering AI initiative of our era - rewriting discovery, delivery, and democratization of precision medicine, powered by collaborations with tech giants @Microsoft & @databricks Tevogen Generics is our commitment to affordable, accessible medicine for American patients at scale. And yes, if we can process trillions (that’s a T) of data points through large-scale AI architectures and make sense of them, we can detect patterns. Debate me. Advanced medicine isn’t just innovation — it is our national security, and that’s not negotiable, regardless of thesis. And, our #Tcell therapy pipeline is more robust than ever. More at TEVOGEN.COM #AIinMedicine #PrecisionMedicine #HealthTech #MAHA $TVGN #oncology #LongCOVID #EBV

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… 🔹Tevogen.AI to explore external market opportunities as a potential revenue source. 🔹Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. 🔹Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. $TVGN #affordable #accessible #celltherapy #DrugDiscovery #Oncology #AI #ArtificialIntelligence @Microsoft @databricks

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… “As a mission-driven innovator, Tevogen.AI believes that AI has the potential to significantly reduce the cost and time required to bring life-saving treatments to patients in need,” said Ryan Saadi, MD, MPH, Founder and @CEO_TEVOGEN_BIO. “We commend the U.S. government for recognizing this potential and setting a national strategy. With a focus on both innovation and equity, our work at @TevogenAI seeks scalable, ethical solutions that expand access to affordable, advanced therapeutics for all Americans.” $TVGN #affordable #accessible #celltherapy #ArtificialIntelligence @WhiteHouse #aiactionplan

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… ▪ Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies ▪ Initiative to support Tevogen Bio’s ExacTcell™ pipeline with a goal of enhancing commercial viability and shareholder value $TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence @Microsoft @databricks

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… $TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence @Microsoft @databricks · Tevogen.AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing wet lab dependency, and accelerating timelines. · Beyond cost savings, Tevogen.AI leadership believes AI-driven drug discovery has the potential to generate billions in top line revenues for companies who are early adopters. · With virology datasets curated and alpha model created, Tevogen.AI will now apply PredicTcell to include oncology, expanding its scope and potentially accelerating cancer immunotherapy development.

⏳ 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐓𝐢𝐦𝐞 𝐂𝐚𝐩𝐬𝐮𝐥𝐞 ⏳ Mittul Mehta CIO and Head of Tevogen.AI in conversation with @bradmehl of @futuresights_hq and @Medium about AI Innovation in Drug Discovery. 👉medium.com/future-sights/… "One of the most interesting use cases that we deal with at Tevogen Bio is analyzing proteomic and genomic data sets in order to predict drug targets. Now that’s core to our science and how we are actually approaching a variety of diseases as opposed to a single one." - Mittul Mehta $TVGN #affordable #accesible #ArtificialIntelligence #biotech

Tevogen: 300+ years of experience in drug development, commercialization, investment banking, & the emerging field of $AI in healthcare. 🌐#Leadership" target="_blank" rel="nofollow noopener">tevogen.com/about/#Leaders… #TechInHealthcare #BiopharmaFuture #AIinHealthcare #GrowthCatalyst $TVGN #Leadership #PurposeDriven